Ironwood Pharmaceuticals (IRWD)
Market Price (2/1/2026): $4.89 | Market Cap: $793.2 MilSector: Health Care | Industry: Pharmaceuticals
Ironwood Pharmaceuticals (IRWD)
Market Price (2/1/2026): $4.89Market Cap: $793.2 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 42% | Weak multi-year price returns2Y Excs Rtn is -105%, 3Y Excs Rtn is -130% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 58% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% | Stock price has recently run up significantly6M Rtn6 month market price return is 534%, 12M Rtn12 month market price return is 109% | |
| Attractive yieldFCF Yield is 8.5% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -10%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -6.7% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 241% | |
| High stock price volatilityVol 12M is 122% | ||
| Key risksIRWD key risks include [1] a significant regulatory delay for its potential blockbuster drug apraglutide, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 42% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% |
| Attractive yieldFCF Yield is 8.5% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -105%, 3Y Excs Rtn is -130% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 58% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 534%, 12M Rtn12 month market price return is 109% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -10%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -6.7% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 241% |
| High stock price volatilityVol 12M is 122% |
| Key risksIRWD key risks include [1] a significant regulatory delay for its potential blockbuster drug apraglutide, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Exceptional 2026 Financial Guidance.
Ironwood Pharmaceuticals announced robust financial guidance for fiscal year 2026, significantly surpassing analyst expectations. This guidance, released in early January 2026, projected total revenues between $450 million and $475 million, a substantial increase from the 2025 guidance of $290 million to $310 million. Additionally, the company anticipated adjusted EBITDA to exceed $300 million in 2026, more than doubling its 2025 projection of over $135 million. This strong outlook was a primary catalyst for the stock's upward movement.
2. Optimized LINZESS Franchise Performance.
A strategic reduction in the list price of LINZESS, effective January 1, 2026, is expected to paradoxically drive higher net sales year-over-year. This is primarily due to the elimination of inflation-related statutory rebates across various channels, including Medicaid, which will improve the overall net pricing. Consequently, LINZESS U.S. net sales are forecast to reach between $1.125 billion and $1.175 billion in 2026, a significant increase from the $860 million to $890 million guided for 2025. This move aims to maintain patient access while enhancing the product's profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The 154.7% change in IRWD stock from 10/31/2025 to 1/31/2026 was primarily driven by a 132.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.92 | 4.89 | 154.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 309 | 339 | 9.9% |
| P/S Multiple | 1.0 | 2.3 | 132.5% |
| Shares Outstanding (Mil) | 162 | 162 | -0.3% |
| Cumulative Contribution | 154.7% |
Market Drivers
10/31/2025 to 1/31/2026| Return | Correlation | |
|---|---|---|
| IRWD | 154.7% | |
| Market (SPY) | 1.5% | 26.0% |
| Sector (XLV) | 7.3% | 20.0% |
Fundamental Drivers
The 540.1% change in IRWD stock from 7/31/2025 to 1/31/2026 was primarily driven by a 504.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.76 | 4.89 | 540.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 318 | 339 | 6.7% |
| P/S Multiple | 0.4 | 2.3 | 504.4% |
| Shares Outstanding (Mil) | 161 | 162 | -0.8% |
| Cumulative Contribution | 540.1% |
Market Drivers
7/31/2025 to 1/31/2026| Return | Correlation | |
|---|---|---|
| IRWD | 540.1% | |
| Market (SPY) | 9.8% | 22.6% |
| Sector (XLV) | 19.2% | 16.8% |
Fundamental Drivers
The 109.0% change in IRWD stock from 1/31/2025 to 1/31/2026 was primarily driven by a 136.9% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.34 | 4.89 | 109.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 378 | 339 | -10.4% |
| P/S Multiple | 1.0 | 2.3 | 136.9% |
| Shares Outstanding (Mil) | 160 | 162 | -1.5% |
| Cumulative Contribution | 109.0% |
Market Drivers
1/31/2025 to 1/31/2026| Return | Correlation | |
|---|---|---|
| IRWD | 109.0% | |
| Market (SPY) | 16.0% | 16.2% |
| Sector (XLV) | 6.8% | 18.8% |
Fundamental Drivers
The -57.6% change in IRWD stock from 1/31/2023 to 1/31/2026 was primarily driven by a -78.9% change in the company's Net Income Margin (%).| (LTM values as of) | 1312023 | 1312026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.52 | 4.89 | -57.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 421 | 339 | -19.4% |
| Net Income Margin (%) | 39.8% | 8.4% | -78.9% |
| P/E Multiple | 10.5 | 27.8 | 164.0% |
| Shares Outstanding (Mil) | 153 | 162 | -5.6% |
| Cumulative Contribution | -57.6% |
Market Drivers
1/31/2023 to 1/31/2026| Return | Correlation | |
|---|---|---|
| IRWD | -57.6% | |
| Market (SPY) | 76.6% | 13.9% |
| Sector (XLV) | 21.4% | 16.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IRWD Return | 2% | 6% | -8% | -61% | -24% | 44% | -57% |
| Peers Return | -8% | 22% | 32% | 3% | 14% | 4% | 81% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| IRWD Win Rate | 42% | 42% | 42% | 33% | 42% | 100% | |
| Peers Win Rate | 43% | 50% | 53% | 52% | 53% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| IRWD Max Drawdown | -21% | -15% | -33% | -71% | -87% | 0% | |
| Peers Max Drawdown | -27% | -35% | -13% | -15% | -25% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BHC, ABBV, ARDX, AMGN, VTRS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/30/2026 (YTD)
How Low Can It Go
| Event | IRWD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -40.9% | -25.4% |
| % Gain to Breakeven | 69.1% | 34.1% |
| Time to Breakeven | 145 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -38.8% | -33.9% |
| % Gain to Breakeven | 63.3% | 51.3% |
| Time to Breakeven | 1,414 days | 148 days |
| 2018 Correction | ||
| % Loss | -55.8% | -19.8% |
| % Gain to Breakeven | 126.3% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to BHC, ABBV, ARDX, AMGN, VTRS
In The Past
Ironwood Pharmaceuticals's stock fell -40.9% during the 2022 Inflation Shock from a high on 10/8/2021. A -40.9% loss requires a 69.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Ironwood Pharmaceuticals (IRWD)
AI Analysis | Feedback
Here are 1-3 brief analogies for Ironwood Pharmaceuticals (IRWD):
- A Vertex Pharmaceuticals for digestive health.
- A Jazz Pharmaceuticals for gut disorders.
AI Analysis | Feedback
- Linzess (linaclotide): A prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults.
- Apraglutide: A glucagon-like peptide-2 (GLP-2) analog currently in Phase 3 development for the treatment of short bowel syndrome (SBS) with intestinal failure.
AI Analysis | Feedback
Ironwood Pharmaceuticals (IRWD) primarily sells its pharmaceutical products to other companies, specifically large drug wholesalers, who then distribute the products to pharmacies, hospitals, and other healthcare providers.
Its major customers are:
AI Analysis | Feedback
null
AI Analysis | Feedback
Thomas McCourt, Chief Executive Officer and Director
Joined Ironwood in 2009 as Senior Vice President of Marketing and Sales and Chief Commercial Officer, advancing to President, interim CEO, and becoming CEO and a board member in 2021. He was instrumental in the success of the company's blockbuster product, LINZESS™. Prior to Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from 2008 to 2009. From 2001 to 2008, he worked for Novartis AG, where he directed the launch and growth of ZELNORM™ and held several senior commercial roles. He was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for PRILOSEC® and NEXIUM®. Mr. McCourt served on the board of directors of Acceleron Pharma Inc., including on the audit and compensation committees, before its acquisition.
Greg Martini, Chief Financial Officer
Assumed the role of Chief Financial Officer in January 2025. In this position, he oversees investor relations, corporate communications, finance and accounting, information technology (IT), facilities, and procurement. Prior to his current role, he served as Vice President of Strategic Financial Planning at Ironwood Pharmaceuticals.
Michael Shetzline, M.D., Ph.D., Chief Medical Officer, Senior Vice President and Head of Drug Development
Joined Ironwood in 2019. Dr. Shetzline is a gastroenterologist and internist with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, he served as Vice President and Head of Gastroenterology Clinical Sciences at Takeda Pharmaceuticals International Co., where he led global clinical development for all GI assets from 2015 to 2019. Prior to Takeda, he was Vice President and Global Head of Gastroenterology at Ferring International Pharmascience Center U.S., Inc. from 2012 to 2015, leading clinical development programs in gastroenterology. He also served as Vice President and Global Program Head, and Head of Translational Medicine GI Discovery at Novartis Pharmaceuticals AG from 2002 to 2012. Dr. Shetzline also served as a gastroenterology program director and assistant professor of medicine at Duke University Medical Center.
John Minardo, Senior Vice President, Chief Legal Officer
Joined Ironwood in August 2021. He brings over 20 years of legal experience within the healthcare and pharmaceutical industries. Before joining Ironwood, Mr. Minardo was Vice President, General Counsel, and a member of the executive leadership team at Seqirus, where he led a global legal team overseeing various activities including business transactions and regulatory matters from 2015 to 2021. Prior to Seqirus, he held increasing roles of responsibility at Novartis from 2007 to 2015, culminating in his service as Vice President, General Counsel, and Chief Compliance Officer at Novartis Influenza Vaccines. Mr. Minardo started his legal career as a litigator at Kaye Scholer LLP. He also helped lead Ironwood's acquisition of VectivBio in 2023.
Tammi Gaskins, Chief Commercial Officer
Assumed the role of Chief Commercial Officer in January 2025. Ms. Gaskins joined Ironwood in July 2020 as Senior Director of Marketing, and previously served as Vice President of Brand Management. Before joining Ironwood, she spent over 20 years at AstraZeneca, where her most recent role was Executive Director of the Diabetes Franchise. She also held positions of increasing seniority within AstraZeneca's Specialty and Primary Care Brands and served as Commercial Director for the Middle East Area in Dubai.
AI Analysis | Feedback
The key risks to Ironwood Pharmaceuticals' business (NASDAQ: IRWD) primarily revolve around its reliance on its flagship product, LINZESS, coupled with recent setbacks in its pipeline and resulting financial pressures.
- Regulatory Setback for Apraglutide: Ironwood's potential "blockbuster" drug, apraglutide, for short bowel syndrome with intestinal failure (SBS-IF), has encountered a significant regulatory hurdle. The U.S. Food and Drug Administration (FDA) is requiring a second Phase 3 trial due to unexpected issues with lower-than-anticipated drug exposure in the initial STARS study, stemming from dose preparation problems. This requirement is expected to delay potential approval until approximately 2029. This delay creates considerable uncertainty, necessitates additional funding for clinical trials, and complicates the company's financial planning, especially as it aimed for apraglutide revenues to align with the eventual patent expiration of LINZESS.
- Reliance on LINZESS and Impending Generic Competition: LINZESS (linaclotide) is Ironwood's primary revenue driver. While some patents covering the formulation of the 72 mcg dose of LINZESS are expected to expire in 2031, other key patents, including the U.S. composition of matter patent, expire in 2026. Moreover, Ironwood and its partner have entered into settlement agreements with generic manufacturers, allowing generic versions of LINZESS (145 mcg and 290 mcg) to enter the U.S. market as early as March 2029, and the 72 mcg dose by March 2029 or August 2030, subject to FDA approval. The introduction of generic competition is expected to significantly impact LINZESS sales and, consequently, Ironwood's overall revenue.
- Financial Strain and Debt Obligations: The combined effect of the delayed apraglutide approval and the impending generic competition for LINZESS is expected to create significant financial strain for Ironwood. The requirement for an additional Phase 3 trial for apraglutide will necessitate further investment, potentially impeding earnings growth and limiting the company's ability to reduce its existing debt. The delay also complicates the refinancing of convertible notes due in June 2026. One analysis indicates Ironwood Pharmaceuticals has a 29.5% probability of financial distress in the next 24 months.
AI Analysis | Feedback
nullAI Analysis | Feedback
Ironwood Pharmaceuticals (symbol: IRWD) focuses primarily on gastrointestinal (GI) diseases. Its main in-market product is LINZESS (linaclotide), and its lead investigational program is apraglutide. Here are the addressable market sizes for these key products: * LINZESS (linaclotide) * **Indication:** Irritable Bowel Syndrome with Constipation (IBS-C), Chronic Idiopathic Constipation (CIC) in adults, and functional constipation in pediatric patients aged 6-17 years old. * **Addressable Market Size:** * In the United States, LINZESS sales reached approximately $1.2 billion in 2022 and are projected to reach approximately $2.15 billion by 2027. * The global market for Irritable Bowel Syndrome (IBS) treatment was estimated at USD 3.64 billion in 2024 and is projected to reach USD 6.02 billion by 2030, growing at a CAGR of 8.8%. North America accounted for the largest revenue share of 37.5% in 2024 within this global market. * More specifically for IBS-C drugs, the global market size was estimated to be around USD 1.2 billion in 2023, with a projected increase to USD 2.3 billion by 2032. North America currently leads this market. * The U.S. constipation treatment market alone surpassed USD 5 billion in 2025. The global constipation treatment market is valued at USD 13.17 billion in 2025 and is forecast to expand to USD 17.98 billion by 2030. * Apraglutide * **Indication:** Short Bowel Syndrome with Intestinal Failure (SBS-IF). * **Addressable Market Size:** Information on a specific global or U.S. addressable market size for Short Bowel Syndrome with Intestinal Failure (SBS-IF) was not found in the provided search results. Therefore, the market size for apraglutide cannot be quantified at this time. * **Return:** nullAI Analysis | Feedback
Here are the expected drivers of future revenue growth for Ironwood Pharmaceuticals (IRWD) over the next 2-3 years:1. Continued Prescription Demand Growth for LINZESS: Despite anticipated pricing headwinds, Ironwood Pharmaceuticals expects continued strong prescription demand growth for its primary product, LINZESS (linaclotide), which is used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). For the full year 2024, LINZESS demonstrated 11% prescription demand growth, with new-to-brand volume growth at 14%. The company anticipates high single-digit prescription demand growth for LINZESS in 2025.
2. Launch and Commercialization of Apraglutide: A significant future revenue driver is the anticipated launch of apraglutide, expected in 2026, for adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Ironwood Pharmaceuticals aims to complete the New Drug Application (NDA) submission for apraglutide by the third quarter of 2025 and is undertaking pre-launch activities for its potential commercialization. The company believes apraglutide has the potential to become a blockbuster therapy and establish a new standard of care.
3. Maximizing LINZESS Profits and Cash Flow: Ironwood is focused on optimizing the profitability and cash flow generated from the LINZESS brand. This includes disciplined expense management and strategic actions to mitigate increased pricing pressures, such as those associated with the Medicare Part D redesign.
AI Analysis | Feedback
<h3>Share Repurchases</h3>
<ul>
<li>In May 2021, Ironwood Pharmaceuticals' Board of Directors authorized a new share repurchase program, allowing the company to repurchase up to $150 million of its outstanding common stock through December 2022.</li>
</ul>
<h3>Share Issuance</h3>
<ul>
<li>During the first quarter of 2025, Ironwood Pharmaceuticals issued common stock related to share-based awards and employee stock purchase plans.</li>
<li>As of April 30, 2025, there were 161,819,848 shares of Class A common stock outstanding.</li>
</ul>
<h3>Outbound Investments</h3>
<ul>
<li>Ironwood Pharmaceuticals acquired VectivBio in a deal made on June 29, 2023.</li>
</ul>Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Ironwood Pharmaceuticals Earnings Notes | 12/16/2025 | |
| Can Ironwood Pharmaceuticals Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.39 |
| Mkt Cap | 8.7 |
| Rev LTM | 11,991 |
| Op Inc LTM | 1,015 |
| FCF LTM | 1,352 |
| FCF 3Y Avg | 1,144 |
| CFO LTM | 1,744 |
| CFO 3Y Avg | 1,539 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 3.8% |
| Rev Chg Q | 10.7% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Mgn LTM | 21.6% |
| Op Mgn 3Y Avg | 21.8% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 17.6% |
| CFO/Rev 3Y Avg | 24.1% |
| FCF/Rev LTM | 15.6% |
| FCF/Rev 3Y Avg | 20.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 8.7 |
| P/S | 3.5 |
| P/EBIT | 3.7 |
| P/E | 24.0 |
| P/CFO | 9.7 |
| Total Yield | 3.6% |
| Dividend Yield | 1.4% |
| FCF Yield 3Y Avg | 9.7% |
| D/E | 0.5 |
| Net D/E | 0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.8% |
| 3M Rtn | 21.1% |
| 6M Rtn | 34.5% |
| 12M Rtn | 24.5% |
| 3Y Rtn | 37.6% |
| 1M Excs Rtn | 3.6% |
| 3M Excs Rtn | 22.8% |
| 6M Excs Rtn | 27.1% |
| 12M Excs Rtn | 13.5% |
| 3Y Excs Rtn | -34.9% |
Price Behavior
| Market Price | $4.89 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 02/03/2010 | |
| Distance from 52W High | -9.3% | |
| 50 Days | 200 Days | |
| DMA Price | $3.91 | $1.81 |
| DMA Trend | up | up |
| Distance from DMA | 25.1% | 169.6% |
| 3M | 1YR | |
| Volatility | 122.2% | 116.3% |
| Downside Capture | 76.31 | 164.02 |
| Upside Capture | 625.17 | 216.10 |
| Correlation (SPY) | 26.0% | 16.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.77 | 2.21 | 2.79 | 2.41 | 0.97 | 0.80 |
| Up Beta | 2.77 | 3.05 | 7.50 | 2.78 | -0.13 | 0.18 |
| Down Beta | -1.82 | 0.08 | -1.64 | 1.48 | 1.09 | 1.00 |
| Up Capture | 1141% | 565% | 1004% | 1134% | 445% | 40% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 19 | 28 | 60 | 111 | 343 |
| Down Capture | 260% | 145% | 78% | -2% | 132% | 106% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 20 | 30 | 58 | 131 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRWD | |
|---|---|---|---|---|
| IRWD | 36.5% | 122.3% | 0.83 | - |
| Sector ETF (XLV) | 7.7% | 17.2% | 0.27 | 15.6% |
| Equity (SPY) | 16.1% | 19.2% | 0.65 | 14.4% |
| Gold (GLD) | 76.5% | 23.4% | 2.38 | 4.5% |
| Commodities (DBC) | 11.1% | 15.9% | 0.48 | 8.4% |
| Real Estate (VNQ) | 5.3% | 16.5% | 0.14 | 9.5% |
| Bitcoin (BTCUSD) | -18.9% | 39.9% | -0.43 | 16.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRWD | |
|---|---|---|---|---|
| IRWD | -13.5% | 70.4% | 0.11 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 17.7% |
| Equity (SPY) | 14.0% | 17.1% | 0.65 | 16.2% |
| Gold (GLD) | 20.8% | 16.5% | 1.03 | 2.7% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | 2.4% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 14.0% |
| Bitcoin (BTCUSD) | 21.1% | 57.5% | 0.56 | 7.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRWD | |
|---|---|---|---|---|
| IRWD | -5.0% | 59.6% | 0.17 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 27.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 24.8% |
| Gold (GLD) | 15.6% | 15.3% | 0.85 | 0.4% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 9.2% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 17.6% |
| Bitcoin (BTCUSD) | 71.5% | 66.4% | 1.11 | 3.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | 31.8% | 63.5% | 92.2% |
| 8/7/2025 | 9.3% | 35.4% | 43.5% |
| 2/27/2025 | -5.3% | -9.9% | -14.6% |
| 11/7/2024 | -7.5% | -14.6% | -31.9% |
| 8/8/2024 | -32.6% | -27.8% | -25.0% |
| 5/9/2024 | -17.0% | -19.2% | -21.8% |
| 2/15/2024 | -3.0% | -3.8% | -41.6% |
| 11/9/2023 | 3.1% | 5.7% | 13.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 11 |
| # Negative | 13 | 12 | 12 |
| Median Positive | 3.4% | 5.4% | 13.5% |
| Median Negative | -3.1% | -6.7% | -14.6% |
| Max Positive | 31.8% | 63.5% | 92.2% |
| Max Negative | -32.6% | -27.8% | -41.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/16/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/16/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/18/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gaskins, Tammi L | Chief Commercial Officer | Direct | Sell | 11192025 | 3.32 | 6,016 | 19,973 | 781,076 | Form |
| 2 | Gaskins, Tammi L | Chief Commercial Officer | Direct | Sell | 8132025 | 0.84 | 1,316 | 1,105 | 202,675 | Form |
| 3 | John, Minardo | Chief Legal Officer | Direct | Sell | 8132025 | 0.84 | 7,754 | 6,513 | 336,318 | Form |
| 4 | Martini, Gregory S | Chief Financial Officer | Direct | Sell | 8132025 | 0.84 | 1,265 | 1,063 | 153,338 | Form |
| 5 | Silver, Ronald | Principal Accounting Officer | Direct | Sell | 8132025 | 0.84 | 2,846 | 2,391 | 232,520 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.